Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU). CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study.
“We believe the profound decreases in plasma tryptase demonstrated in our Phase 1a study suggest CDX-0159 has significant potential as a disease-modifying therapeutic for mast cell driven disorders,” said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. “This latest study will build on prior results as we seek to establish the safety and potential clinical benefit of multi-dosing in a disease setting fundamentally driven by mast cells—CSU. In the coming weeks, we will further expand these efforts, initiating a second Phase 1b study in chronic inducible urticaria.”
The Phase 1b study is a randomized, double-blind, placebo-controlled clinical trial designed to assess the safety of multiple ascending doses of CDX-0159 in patients with CSU who remain symptomatic despite treatment with antihistamines. Secondary and exploratory objectives include pharmacokinetic and pharmacodynamic assessments, including measurement of tryptase and stem cell factor levels and clinical activity outcomes (impact on urticaria symptoms, disease control, clinical response) as well as quality of life assessments. The study is expected to enroll approximately 40 patients with CSU across four cohorts (8 CDX-0159; 2 placebo). CDX-0159 dosing for each cohort is as follows:
CDX-0159 will be administered intravenously as add on treatment to H1-antihistamines, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists.
More information about this study is available on www.cinicaltrials.gov (Identifier: NCT04538794). Results from the study are expected in the second half of 2021.
CSU is one of the most frequent dermatologic diseases with a prevalence of 0.5-1% of the total population (up to 3.2M in the US). Mast cell activation drives disease through the release of histamines, leukotrienes and chemokines, resulting in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Currently approved therapies target symptomatic relief. About 50% of patients with CSU achieve symptomatic control with antihistamines or leukotriene receptor antagonists. Omalizumab, an IgE inhibitor, provides relief for roughly half of the remaining antihistamine/leukotriene refractory patients. Celldex believes that CDX-0159 has significant potential to interfere with mast cells at multiple steps upstream of current treatments, which, in turn, could be disease modifying for patients.
Forward Looking Statement
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Smart City with a Social Conscience
AI Use Case